Epigenetic reversal of acquired resistance to 5-fluorouracil treatment
Published version of a preprint
The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
Acquired and intrinsic resistance still remains a limitation to the clinical use of 5-fluorouracil (5-FU). The contribution of epigenetic changes to the development of drug resistance remains to be elucidated. Several genes that are hypermethylated and silenced have been identified in colorectal cancer. Based on the findings described in the accompanying article, we hypothesized that acquired resistance to “pulse” 5-FU has an epigenetic origin and might be reversed. Here, we present a novel therapeutic approach to circumvent clinical resistance to bolus 5-FU, that is, treatment of bolus 5-FU-resistant colorectal cancer cells with low-dose 5-azadeoxycytidine (DAC), an inhibitor of DNA hypermethylation, restored sensitivity to 5-FU as well as 5-fluorouridine. Moreover, treatment of nude mice bearing a 5-FU-resistant tumor, characterized by decreased levels of UMP kinase (UMPK), with DAC overcame resistance to bolus 5-FU. DAC-mediated restoration of 5-FU sensitivity was associated with increases in UMPK levels. An increase in UMPK protein and mRNA levels following treatment with low-dose DAC was observed in cultured bolus 5-FU-resistant colorectal cancer cells (HCT-8) and in mice bearing these tumors. We conclude that DAC-mediated restoration of sensitivity to bolus 5-FU is mediated at least in part by increased UMPK levels and clinical resistance to 5-FU due to decreased UMPK in colorectal cancer may be overcome by including methylation inhibitors such as DAC. [Mol Cancer Ther 2009;8(5):1045–54]
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, DNMT inhibitors were demonstrated to restore 5-FU sensitivity to 5-FU-resistant CRC cells in mouse xenograft tumor models [162,163].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [163]
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
EMBOSS: the European molecular biology open software suite.
Rice, P., Longden, I., & Bleasby, A. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02024-2 · Cited by 9,466
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 2×
“Interestingly, IFN-g has been shown to up-regulate the activities of the 5-FU anabolic enzyme thymidine phosphorylase and uridine phosphorylase resulting in enhanced 5-FU activation (36).”
BackgroundMethodGene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
CpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J.-P. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,523
Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?
Baylin, S. B., & Ohm, J. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1799 · Cited by 1,639
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Cited by
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813
Epigenetics and Colorectal Cancer Pathogenesis
Bardhan, K., & Liu, K. (2013) · Cancers · doi:10.3390/cancers5020676 · Cited by 252
Crea, F., Nobili, S., Paolicchi, E., Perrone, G., Napoli, C., Landini, I., Danesi, R., & Mini, E. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.08.001 · Cited by 137
Nars, M. S., & Kaneno, R. (2013) · International Journal of Cancer · doi:10.1002/ijc.27801 · Cited by 120
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Moreover, DNMT inhibitors were demonstrated to restore 5-FU sensitivity to 5-FU-resistant CRC cells in mouse xenograft tumor models [162,163].”
Metadata
- Authors
- Humeniuk, R., Mishra, P. J., Bertino, J. R., & Banerjee, D.
- Affiliations
- Rutgers Cancer Institute (US)
- National Institutes of Health (US)
- Venue
- Molecular Cancer Therapeutics
- Published
- 2009-05-01
- Volume
- 8
- Issue
- 5
- Pages
- 1045-1054
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2117321270
- Cited by
- 28
- References
- 47
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 2 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 2 · 2013: 2 · 2012: 2
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- 5-fluorouracil resistance, epigenetic drug resistance, DNA methylation inhibitors, UMP kinase, colorectal cancer, acquired drug resistance, 5-fluorouridine, HCT-8 cells
- MeSH terms
- Decitabine, Animals, Antimetabolites, Antineoplastic, Azacitidine, Base Sequence, Fluorouracil, Humans, Mice, Nude, Molecular Sequence Data, Nucleoside-Phosphate Kinase, Promoter Regions, Genetic, Uridine, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, CpG Islands, Drug Resistance, Neoplasm, DNA Methylation, RNA Stability, Xenograft Model Antitumor Assays, Gene Order, Cell Line, Tumor, Mice, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0717
- The paper
- Humeniuk, R., Mishra, P. J., Bertino, J. R., & Banerjee, D. (2009). Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0717
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.